Susan G. Komen® Houston MBC Impact Series presents
2020 South Central Metastatic Breast Cancer Conference
SATURDAY, FEBRUARY 7-8, 2020 • NORRIS CONFERENCE CENTER
CityCentre in Houston, TX
Susan G. Komen® Houston, in conjunction with Theresa’s Research Foundation, will host its second South Central Metastatic Breast Cancer Conference- A Conference for Those Living with Advanced or Metastatic Breast Cancer at the Norris Conference Centers – Houston CityCentre. The Conference will be held on February 7-8, 2020.
Designed by patients for patients, the South Central Metastatic Breast Cancer Conference is uniquely suited to the needs of the metastatic breast cancer (MBC) community. Building on the success of the first conference in 2018, the agenda is designed to provide patients and caregivers an opportunity to learn about scientific breakthroughs and emerging treatment options as well as identify ways to improve quality of life by going beyond the oncologist’s office. Finally, the conference allows participants to gain support and build community. For questions regarding the Conference, please email email@example.com.
Free of charge, the conference is open to metastatic patients, survivors, caregivers and co-survivors.
Online registration is now closed, however walk in registration is available.
Contact firstname.lastname@example.org for any questions.
Live Stream from the 2020 South Central Metastatic Breast Cancer Conference
Matthew J. Ellis, M.D., Ph.D.,
Director, Lester and Sue Smith Breast Care Center
Dr. Matthew Ellis serves as director of the Lester and Sue Smith Breast Center at Baylor. This year, Dr. Ellis has been awarded the Susan G. Komen® Brinker Award for Scientific Distinction in Clinical Research for his contributions to understanding the genomics of breast cancer and translating this knowledge to the clinic in order to improve the efficacy of breast cancer treatment. Susan G. Komen® annually recognizes the scientists who have made the most significant advances in breast cancer research and medicine.
Ellis is a native of the United Kingdom. He completed his medical degree from Queens’ College & School of Clinical Medicine at the University of Cambridge in England, postgraduate clinical training at the Royal College of Physicians in London and Ph.D. training at the Royal Postgraduate Medical School at the University of London.
Prior to coming to Baylor, Ellis was at Washington University School of Medicine, where he served as professor of medicine, head of breast oncology and head of medical oncology. Prior to Washington University, Ellis served on the faculty at Duke University and Georgetown University.
His research has unveiled groundbreaking new information about mutations in breast cancer and their clinical relevance. He has been instrumental in developing a Genome Atlas and Therapeutic Road Map for estrogen receptor positive breast cancer. Most recently, he has found that metastatic breast tumors initially positive for the estrogen receptor frequently harbor mutations and translocations in the receptor that render the tumor resistant to endocrine therapies used to block estrogen.
Ellis is a funded scholar of the Cancer Prevention and Research Institute of Texas and Susan G. Komen.
Debu Tripathy, MD, Professor and Chairman,
Department of Breast Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center
Dr. Debu Tripathy is Professor and Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center. Before joining MD Anderson, Dr. Tripathy worked at the Norris Comprehensive Cancer Center at the University of Southern California. He received his medical degree from Duke University Medical School and completed a clinical fellowship in Hematology/Oncology at University of California at San Francisco. Dr. Tripathy’s clinical research focuses on evaluating and developing new breast cancer therapies. Dr. Tripathy leads MD Anderson’s Advanced Breast Cancer Program, a multi-department effort designed to increase the median survival time for patients with advanced breast cancer, improve the quality of life of patients, and find a cure for stage IV breast cancer. He has published numerous original laboratory and clinical research articles in the area of breast cancer and serves on several editorial boards, study sections, and societies.
Tripathy is a funded scholar of the Cancer Prevention and Research Institute of Texas and Susan G. Komen.
|FEBRUARY 7-8, 2020 / Norris Conference Center CITYCENTRE / Houston, TX
Sponsors & Exhibitors